There is no single, universally accepted dose of NAD+ or its precursors. However, a growing number of human clinical trials are providing useful information on the doses of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that have actually been evaluated in research. These studies help to determine which dosage ranges can increase NAD+-related biomarkers, how well individual amounts were tolerated, and whether higher doses consistently lead to stronger functional effects. However, they do not establish a single ideal dose for everyone. Individual response may vary depending on age, health status, metabolism, medications taken, product formulation, and the specific effect being studied.
In this guide, we discuss oral doses of NR and NMN used in published human studies, differences in dosage between administration routes, tolerance of larger amounts, and the reasons why increasing the dose does not necessarily mean greater benefits.
We also explain why consulting a doctor or other appropriately qualified healthcare professional about supplementation with NAD+ precursors is particularly important in the case of co-existing medical conditions or when taking medications.
It is also important to define the scope of this article.
Because oral ingestion of intact NAD+ faces significant absorption limitations, the majority of human oral dosage studies focus on NAD+ precursors rather than NAD+ itself.
The two best-researched precursors are NR and NMN.
Typical oral doses of NAD+: initial dose versus maintenance dose
In human clinical trials, a fairly wide range of NR and NMN doses has been evaluated.
An analysis of the actual doses used in studies is more useful than a general statement such as „100 to 2,000 mg per day”, as different doses led to different changes in NAD+ biomarkers and different study outcomes.
Nicotinamide riboside (NR)
In an early human pharmacokinetic study, single doses of NR of 100 mg, 300 mg, and 1000 mg were evaluated.
All three doses caused a dose-dependent increase in NAD+-related metabolites in the blood. This demonstrated that increasing the amount of NR can lead to progressively greater changes in NAD+ metabolism. [1]
A similar pattern was observed in the long-term studies.
In an eight-week, double-blind, placebo-controlled trial involving 140 healthy, overweight individuals, participants were given 100 mg, 300 mg or 1,000 mg of NR daily. [2]
After two weeks, the NAD+ level in whole blood had increased by approximately 22% in the 100 mg group, 51% in the 300 mg group and 142% in the 1000 mg group.
After eight weeks, the increases were approximately 10%, 48% and 139% respectively. [2]
No significant difference in the incidence of adverse events was observed between the NR and placebo groups at any of the doses studied.
Another randomised, placebo-controlled crossover trial involved 24 healthy middle-aged and elderly participants, who received 1,000 mg of NR daily for six weeks.
This dose was generally well tolerated and no serious adverse events were reported.
Researchers also observed a tendency towards lower blood pressure and reduced arterial stiffness, although these findings were not sufficient to recognise NR as a treatment for cardiovascular diseases. [3]
Even larger amounts were used in some studies.
NR doses of around 2,000 mg per day, often divided into two 1,000 mg doses, were evaluated over a period ranging from a few weeks to around three months. [4]
In studies conducted to date, these higher doses have generally not raised any significant safety signals.
At the same time, some studies found no significant improvement in the main functional or metabolic parameters assessed, despite marked changes in NAD+ metabolism.
That is an important distinction.
A greater increase in NAD+ biomarkers does not necessarily mean a proportionally greater clinical benefit.
Nicotinamide mononucleotide (NMN)
Human studies have also assessed a wide range of NMN doses.
In one of the early safety studies involving healthy Japanese men, single doses of 100 mg, 250 mg and 500 mg were evaluated.
At none of these doses did the researchers observe any significant changes in vital signs or routine laboratory test results. [5]
Lower daily doses were also evaluated during long-term use.
In one of the 12-week studies, 250 mg of NMN was administered daily and no serious adverse effects were reported.
Higher doses were used in larger studies assessing dose-response relationships.
In a randomised, placebo-controlled trial involving 80 healthy middle-aged and older adults, participants were given 300 mg, 600 mg or 900 mg of NMN daily for 60 days. [6]
Blood NAD+ levels increased in a dose-dependent manner in all three groups receiving NMN.
Improvements in the six-minute walk test results were also observed in the 600 mg and 900 mg groups.
These functional results are interesting, but they should be interpreted in the context of the specific study, rather than as evidence that such doses will improve physical performance in everyone.
At the upper end of the dose range studied, one of the pharmacokinetic studies utilised a pharmaceutical-grade microcrystalline NMN formulation.
Participants were given 1,000 mg once a day or 1,000 mg twice a day, which amounted to a maximum total of 2,000 mg per day for 14 days. [7]
Both regimens caused a significant, dose-dependent increase in blood NAD+ levels.
The overall incidence of adverse events was similar in the active and placebo groups.
In another four-week safety study, 1250 mg of NMN once daily was evaluated specifically in 31 healthy adults.
This dose has also been described as well tolerated. [8]
What do these dose ranges mean?
The published literature provides a useful general overview, but does not constitute a formal recommendation regarding dosage.
Lower doses of NR or NMN, ranging from approximately 100 to 300 mg, produced measurable changes in NAD+-related biomarkers in human studies.
The increases were generally smaller than those observed with higher doses.
Doses of around 600–1,000 mg per day often resulted in greater changes in NAD+ biomarkers.
In some studies, additional functional outcomes, such as an improvement in the results of the six-minute walk test, were also observed at these doses. [6]
Doses exceeding 1,000 mg and reaching around 2,000 mg per day were also studied.
Over relatively short observation periods, higher amounts were generally well tolerated.
However, they did not consistently lead to proportionally greater functional benefits.
The conclusion best supported by available research is therefore that higher doses may cause greater changes in NAD+ biomarkers, but the relationship between dose and significant health effects is not consistently linear.
Daily or weekly use: what is used in research?
Almost all published human studies on NR and NMN use daily administration.
Weekly or highly irregular patterns have been studied to a much lesser extent.
Daily protocols typically involve one dose per day or a dose split into two portions, often taken in the morning and evening.
This method of conducting research reflects changes in NAD+ precursor metabolism over time.
Studies measuring NAD+ levels during regular supplementation suggest that blood NAD+ levels may rise gradually and, after around two weeks of consistent daily use, approach a plateau.
Once supplementation has ended, levels may fall again.
This pattern supports the hypothesis that regular intake is needed to maintain elevated NAD+-related biomarkers.
It does not prove, however, that every person must take these compounds daily.
Crucially, no adequate studies involving humans have been conducted directly comparing daily versus weekly or intermittent dosing.
There is little direct clinical data on regimens such as once-weekly dosing or five days on and two days off.
Therefore, claims that cyclical use is better, safer or equally effective remain unsubstantiated by direct comparative studies.
If a commercial product recommends an intermittent regimen, this is usually the manufacturer’s protocol rather than a dosing regimen established in direct clinical trials.
How does the dosage vary depending on the form of the supplement?
Most of the dosing data discussed above come from studies on standard oral capsules or tablets.
This matters because doses cannot be automatically transferred between different delivery methods.
Capsules and tablets
Standard oral capsules and tablets have the most extensive body of human research.
Most clinical trials involving NR and NMN use precisely these conventional oral forms.
The dose ranges described above therefore apply primarily to products containing NAD+ precursors that are taken orally.
For this reason, studies on capsules and tablets currently provide the clearest point of reference when discussing oral doses of NAD+ precursors.
Sublingual NAD+ products
Sublingual products are designed to be dissolved under the tongue.
The anticipated benefit is that part of the active substance can be absorbed by the oral mucosa and thereby partially bypass the gastrointestinal tract.
This is a sound pharmaceutical concept.
However, no adequate human studies have been conducted to determine whether sublingual NR, NMN or NAD+ require a lower or higher dose than standard oral capsules to achieve a comparable change in NAD+ levels.
No controlled human study has been identified that directly compares the absorption of the same dose of the precursor administered sublingually and orally.
For this reason, sublingual dosage instructions are usually set by manufacturers rather than based on confirmed dose equivalence studies.
Liposomal NAD+
The liposomal delivery method has slightly more research evidence to support it than sublingual NAD+.
In a randomised, placebo-controlled trial of a specific liposomal NAD+ formulation, a significant increase in intracellular NAD+ was observed after a short period of treatment.
At the time to which these data refer, however, the study was available as a preprint and had not yet undergone the formal peer-review process.
The aim of liposomal delivery is to encapsulate NAD+ within a lipid structure, which can protect the molecule during digestion and potentially improve its absorption.
If this mechanism works effectively, a liposomal formulation could, in theory, produce a greater biological effect with a lower stated milligram dosage than a standard formulation.
However, this has not been confirmed in a peer-reviewed, direct human trial comparing equivalent doses of liposomal NAD+ with standard NR, NMN or non-liposomal NAD+.
Therefore, the doses of NR and NMN in capsules described above cannot be reliably converted into an „equivalent” liposomal dose.
Intravenous and injectable NAD+
Intravenous and injectable NAD+ falls into a completely different dosage category.
These routes bypass absorption from the digestive tract.
Therefore, milligram-to-milligram comparisons with oral NR or NMN are not appropriate.
In one controlled clinical trial investigating intravenous NAD+ in a specific patient population, only 10 mg daily was used for a short period.
This does not mean that 10 mg of NAD+ administered intravenously is equivalent to 500 mg or 1,000 mg of oral NR or NMN.
The route of administration, systemic exposure, metabolism and pharmacokinetics are entirely different.
Evidence relating to oral precursors and directly administered NAD+ should therefore be interpreted separately.
What symptoms might indicate that you are taking too much?
NR and NMN have generally been shown to be well tolerated in the short term in published human studies.
This also applies to studies using doses approaching approximately 2,000 mg per day.
However, good tolerability in a controlled trial does not mean that every dose is suitable for everyone.
It also does not confirm the long-term safety of the highest quantities tested.
Some studies have reported mild adverse reactions.
These included gastrointestinal complaints, nausea, changes in bowel habits, headaches, fatigue and occasional sleep disturbances.
Skin flushing may also occur, although this effect is much more strongly associated with high doses of niacin, or nicotinic acid, than with NR or NMN.
In some studies, NR has also been reported to cause flushing-like symptoms.
Importantly, a similar incidence of mild symptoms was observed in participants receiving a placebo. [2]
This means that the appearance of a symptom during supplementation does not necessarily mean it was caused by the NAD+ precursor.
However, persistent or worsening symptoms require attention.
Prolonged nausea, gastrointestinal discomfort, unusual fatigue, sleep disturbances or other unexpected symptoms may indicate that a given amount or formulation is poorly tolerated.
Discontinuing use of the product and discussing persistent symptoms with a suitably qualified healthcare professional is more appropriate than assuming discomfort means the product is „working”.
Commercial products may further complicate interpretation, as portion sizes may differ significantly from the amounts assessed in clinical trials.
Some formulations contain multiple ingredients.
Others use proprietary blends.
Therefore, before comparing a product with published dosage data, you should check the exact content of NR, NMN, niacin or nicotinamide.
How should the dose be adjusted according to the body’s response?
The response to NAD+ precursors varies from person to person.
Clinical trials usually present average results for entire groups, rather than predicting the response of each individual participant.
Therefore, the highest dose used in the study should not automatically be regarded as the most appropriate for individual use.
Lower doses provide useful information regarding tolerance and biomarker responses.
Studies using approximately 100–300 mg of NR or NMN have shown that such doses can influence biomarkers associated with NAD+. [1,2,6]
Higher doses, particularly in the range of 600–1000 mg, often resulted in greater changes in biomarkers.
In some studies, additional functional effects have also been reported at these doses. [3,6]
The time taken to assess the responses is also important.
NAD+ related biomarkers can fluctuate for approximately the first two weeks of regular supplementation.
Assessing a particular dose after just one or two days may therefore provide little information about the long-term response to NAD+ observed in clinical trials.
Another important rule is simple: more does not necessarily mean better.
Several studies using approximately 1000–2000 mg per day successfully increased NAD+ biomarkers, but improvements in every functional parameter tested were not observed. [4]
This means that the dose–response relationship varies depending on what is being measured.
The level of NAD+ in the blood may continue to rise, whilst another parameter under investigation remains unchanged.
This distinction is important both when interpreting clinical trials and when assessing marketing claims about supplements.
Why is it worth discussing NAD+ dosage with your doctor?
Most studies on NAD+ precursors have involved relatively well-defined groups of participants.
Middle-aged and older people are particularly well represented.
Some studies involved healthy participants.
Others focused on people who were overweight, obese or had specific medical conditions.
These results cannot automatically be applied to every population.
A healthcare professional can help assess to what extent the populations from the studies correspond to an individual's personal health situation.
This is particularly important for people with cardiovascular, liver or kidney diseases, or metabolic disorders.
Some of these conditions are themselves linked to changes in NAD+ metabolism, and clinical trials concerning NAD+-related interventions have yielded ambiguous results.
Another issue is the medication being taken.
Formal studies of the interaction between NR and NMN remain limited.
This is particularly important when several supplements or medicines that affect glucose regulation, blood pressure, liver metabolism or other metabolic pathways are being taken at the same time.
Pregnant and breastfeeding women are also very under-represented in studies on NAD+ precursors.
Similarly, children and young people have not been adequately studied.
The data discussed in this guide do not, therefore, allow us to determine the appropriate dose for these groups.
The issue of cancer is also more complex.
NAD+ metabolism is involved in proper DNA repair and cell function, but NAD+ is also utilised by rapidly dividing cells, including many cancer cells.
As the relationship between NAD+ metabolism and tumour biology may vary depending on the tissue and the specific disease, people with a personal history of cancer or a significant risk of developing cancer should discuss supplementation with NAD+ precursors with a suitably qualified healthcare professional, rather than relying solely on studies involving the general population.
A specialist can also help assess whether the supplement is needed at all.
Published research shows that NR and NMN may increase NAD+-related biomarkers.
They do not prove, however, that every healthy person will benefit from striving to maximise these biomarkers.
NAD+ precursor doses investigated in humans
| Association | Tested quantity | Research background | Main outcome |
|---|---|---|---|
| NR | 100 mg | Single-dose / pharmacokinetic studies | Increase in NAD+-related metabolites [1] |
| NR | 300 mg | Pharmacokinetic and long-term studies | A greater increase in NAD+ than with 100 mg [1,2] |
| NR | 1000 mg | Many studies involving humans | Significant increase in NAD+; generally well tolerated [2,3] |
| NR | Up to 2,000 mg per day | Higher dose trials | Generally good short-term tolerance; inconsistent functional benefits [4] |
| NMN | 100 mg | Single-dose safety study | No significant clinical safety changes [5] |
| NMN | 250 mg/day | Longer studies involving humans | Generally well tolerated |
| NMN | 300 mg/day | A study of dose-response relationships | Blood NAD+ increase [6] |
| NMN | 600 mg per day | A study of dose-response relationships | A greater increase in NAD+; an improvement in the walking test was observed [6] |
| NMN | 900 mg/day | A study of dose-response relationships | A greater increase in NAD+; an improvement in the walking test was observed [6] |
| NMN | 1250 mg/day | A four-week safety trial | A dose described as well tolerated [8] |
| NMN | Up to 2,000 mg per day | Pharmacokinetic studies | A significant increase in NAD+; a similar incidence of adverse events to that seen with placebo [7] |
These values represent the quantities used in the studies.
They are not standardised recommended doses.
Frequently asked questions about NAD+ dosage
How much NAD+ should be taken daily?
There is no generally accepted daily dose for NAD+ or its precursors. In human studies, NR and NMN have been evaluated across a wide range, often from around 100 mg to 1,000 mg per day, with some studies involving doses of up to around 2,000 mg per day. However, these are research protocols, not approved or suitable doses for every individual.
What is the typical dose of NMN in research?
In human trials, doses of 250 mg, 300 mg, 600 mg, 900 mg, 1,000 mg and 1,250 mg of NMN per day, whilst some short-term pharmacokinetic studies used doses of up to 2,000 mg. Blood NAD+ levels generally increased with dose, but higher doses did not consistently lead to proportionally greater functional benefits. [6–8]
What is the typical dose of NR in research?
In NR studies, 100 mg, 300 mg and 1000 mg per day were frequently used, and some studies evaluated amounts reaching approximately 2000 mg per day. Higher doses generally led to a greater increase in NAD+ biomarkers, but clinical outcomes varied between studies. [1–4]
Is 1000 mg of NMN too much?
A dose of 1000 mg of NMN has been used in human clinical trials, and some short-term studies have evaluated even larger amounts. [7,8]
However, this does not mean that 1,000 mg is suitable for everyone, particularly as long-term safety data and information regarding various health conditions remain limited.
Is 1000 mg of NR too much?
In human studies, a daily dose of 1,000 mg of NR has been assessed on numerous occasions, and good tolerability has generally been observed over the study periods. [2,3]
In some studies, up to around 2000 mg daily was used, but a higher amount did not consistently lead to proportionally greater functional benefits.
Is a higher dose of the NAD+ precursor better?
Not necessarily.
Higher doses of NR or NMN often result in a greater increase in blood NAD+ levels, but several studies have shown that greater changes in biomarkers do not automatically translate into better metabolic, cardiovascular, physical or other functional outcomes. [2,4,6]
Should NR or NMN be taken daily?
Most published studies involving humans have used daily administration, usually once or twice daily.
Adequate studies directly comparing daily dosing with weekly, intermittent or cyclical dosing have not been conducted, therefore claims that non-daily regimens are equally effective or better remain uncertain.
How long do you have to wait for an increase in NAD+ levels?
Human supplementation studies suggest that NAD+-related biomarkers can begin to change relatively quickly and approach a plateau after about two weeks of regular precursor intake.
However, this time may vary depending on the compound, dose, study design and individual metabolism.
Does sublingual NAD+ work more powerfully than capsules?
This has not been confirmed in controlled human studies.
Sublingual products are promoted as a potential solution to improve absorption, but there are no reliable dose-equivalence studies showing that a specific sublingual amount provides the same or greater increase in NAD+ than a standard NR or NMN capsule.
Does liposomal NAD+ require a smaller dose?
Theoretically it is possible, but it has not been confirmed.
Liposomal delivery systems are intended to improve the protection and absorption of substances, but there is a lack of peer-reviewed, direct human studies determining the equivalent dose of liposomal NAD+ compared to standard NR or NMN capsules.
Can you take too much NR or NMN?
High doses were generally well tolerated in short-term human trials, but this does not imply that they are completely safe.
Some studies have reported mild gastrointestinal symptoms, headaches, fatigue, skin redness and changes in sleep patterns; however, the long-term safety of high daily doses remains insufficiently understood.
Limitations of current research
Most data on oral NAD+ dosing comes from NR and NMN studies, rather than NAD+ itself.
This is due to limitations on the absorption of orally administered NAD+ and the significantly greater number of studies on supplementation with precursors.
Another limitation is the dominance of daily dosing in the clinical literature.
No appropriate direct comparisons were carried out between daily, weekly, intermittent and cyclical regimens.
This means that the research provides much more information about regular daily use than about alternative regimens.
Different delivery forms create a further gap in the evidence.
The equivalence of sublingual doses to standard capsules has not been established.
Similarly, it is not currently possible to reliably convert capsule doses into liposomal doses.
Although liposomal delivery may affect absorption, robust direct comparative data in humans remain limited.
The study populations are also relatively narrow.
A significant proportion of the available studies involve healthy individuals, those who are overweight or obese, and middle-aged and older adults.
Children, adolescents, pregnant women and breastfeeding mothers are poorly represented or entirely absent from these studies.
Another significant limitation is long-term safety.
Many studies last for several weeks or months.
Even if higher doses, such as 1000–2000 mg daily, are well tolerated during such periods, this does not confirm the safety of continuous use of the same amounts over many years.
Finally, biomarker response and functional response are not the same.
Higher doses often lead to a greater increase in NAD+-related parameters.
However, they do not consistently lead to greater improvements in physical fitness, metabolism, cardiovascular parameters, cognitive function or other health outcomes.
Available studies therefore help to determine the quantitative ranges assessed in humans, but do not allow a single optimal oral dose of the NAD+ precursor to be established for every person and every purpose.
Disclaimer
This article is intended solely for educational and scientific purposes. It does not constitute medical advice, individual dosage advice, treatment recommendations or advice on the use of NAD+, nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin, nicotinamide or any related supplement.
The dose ranges presented in the article describe the amounts used in published human studies. They should not be interpreted as approved, optimal or universally safe daily doses. NAD+ and its precursors are not approved by the FDA or EMA to treat, prevent or cure any disease, and the regulatory status may vary depending on the compound and jurisdiction.
Short-term human studies have generally shown good tolerance to several doses of NR and NMN, including relatively high amounts. However, long-term safety, drug interactions, and appropriate dosing in many population groups remain insufficiently understood.
References
[1] Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948
[2] Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomised, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
[3] Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. https://doi.org/10.1038/s41467-018-03421-7
[4] Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: A randomised, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease, 3, 17. https://doi.org/10.1038/s41514-017-0016-9
[5] Irie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., Yamashita, K., Shigaki, S., Ono, T., Yukioka, H., Okano, H., Nabeshima, Y., Imai, S., & Yasuda, K. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160. https://doi.org/10.1507/endocrj.EJ19-0313
[6] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomised, multicentre, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[7] Pencina, K. M., Lavu, S., Dos Santos, M., Beleva, Y. M., Cheng, M., Livingston, D., & Bhasin, S. (2023). MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. The Journals of Gerontology: Series A, 78(1), 90–96. https://doi.org/10.1093/gerona/glac049
[8] Fukamizu, Y., Uchida, Y., Shigekawa, A., Sato, T., Kosaka, H., & Sakurai, T. (2022). Safety evaluation of oral administration of β-nicotinamide mononucleotide in healthy adult men and women. Scientific Reports, 12, 14442. https://doi.org/10.1038/s41598-022-18272-y